Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock. "Considering the recent market challenges, the share price ...

May 16 (UPI) --Novo Nordisk announced Friday that CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday that Jorgensen will continue as CEO ...

Novo Nordisk CEO Lars Fruergaard Jørgensen to step down amid board and market pressure. Despite leadership changes, the company maintains its strategy. Unlock your all-in-one trading dashboard ...

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years in the role, during which he led the company to an all-time high in the markets. Despite being the first to ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug ...

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would ...

Shares of Novo Nordisk (NYSE: NVO) are up on Tuesday. The company's stock gained 3.9% as of 2:40 p.m. ET today and was up as much as 4.5% earlier in the day. The move up comes as the S&P 500 and ...

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

Novo Nordisk has submitted an "Ozempic pill" to the FDA for approval. The new pill will probably be popular (if approved). However, making it will require Novo Nordisk to ramp up semaglutide ...

Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 currently. Several factors have contributed to this downward trend.